Analyst Reco. Inhibrx, Inc.

Equities

INBX

US45720L1070

Delayed Nasdaq Other stock markets 10:32:55 2024-06-07 am EDT			5-day change	1st Jan Change
16.91 ^USD	+4.13%		-52.39%	-55.53%

Jun. 04	Inhibrx Biosciences Insider Bought Shares Worth $4,927,580, According to a Recent SEC Filing	MT
May. 31	Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Biotechnology Select Industry Index	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Inhibrx Biosciences Insider Bought Shares Worth $4,927,580, According to a Recent SEC Filing	Jun. 04	MT
JMP Securities Downgrades Inhibrx to Market Perform From Market Outperform	Jan. 23	MT
JMP Securities Adjusts Inhibrx Price Target to $27 From $35, Maintains Market Outperform Rating	23-08-23	MT
JMP Securities Adjusts Price Target on Inhibrx to $35 From $40, Maintains Market Outperform Rating	23-03-08	MT
Credit Suisse Lowers Inhibrx's Price Target to $46 From $48, Keeps Outperform Rating	22-11-08	MT
Evercore ISI Raises Inhibrx's Price Target to $60 From $54, Maintains Outperform Rating	22-10-05	MT
Credit Suisse Lowers Inhibrx's Price Target to $48 from $53, Updates Model to Reflect Q2 Actuals; Keeps Outperform Rating	22-08-09	MT
SMBC Nikko Starts Inhibrx at Outperform With $40 Price Target	22-03-16	MT
JMP Securities Adjusts Inhibrx Price Target to $40 From $53, Maintains Market Outperform Rating	22-03-02	MT
Credit Suisse Raises Inhibrx's PT to $53 from $44 After Chat with CEO, Notes Higher-than-Consensus Q3 Revenue; Keeps Outperform Rating	21-11-10	MT
JMP Securities Adjusts Price Target on Inhibrx to $53 From $46, Maintains Market Outperform Rating	21-11-02	MT
INHIBRX : JMP Securities Starts Inhibrx at Market Outperform with $46 Price Target	21-09-21	MT
INHIBRX : Credit Suisse Adjusts Inhibrx' Price Target to $44 from$28, Keeps Outperform Rating	21-02-03	MT
INHIBRX : Jefferies Adjusts Inhibrx PT to $50 From $30, Maintains Buy Rating	20-12-21	MT
INHIBRX : Credit Suisse Adjusts Inhibrx' Price Target to $28 from $26, Keeps Outperform Rating	20-11-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer